Literature DB >> 12183021

Increased levels of 3-hydroxykynurenine in different brain regions of rats with chronic renal insufficiency.

Joanna Topczewska-Bruns1, Dariusz Pawlak, Ewa Chabielska, Anna Tankiewicz, Wlodzimierz Buczko.   

Abstract

Tryptophan (TRP) metabolism via the kynurenine pathway leads to formations of neuroactive substances like kynurenine (KYN) and 3-hydroxykynurenine (3-HK), which may be involved in the pathogenesis of several human brain diseases. 3-Hydroxykynurenine especially is known to have strong neurotoxic properties. The generation of reactive oxygen species (ROS) leads to neuronal cell death with apoptotic features. Because the chronic renal insufficiency (CRI) results in disturbances in the functioning of the central nervous system (CNS), it is conceivable that the metabolism of some kynurenines may be altered and could play an important role in uremic encephalopathy. The levels of TRP, KYN and 3-HK were measured in the plasma and in different brain regions of uremic rats. The total plasma concentration of TRP as well as in all the studied brain samples was significantly diminished during uremia. Surprisingly, the level of KYN and 3-HK were elevated both in the plasma and different brain regions of CRI animals. KYN concentrations were approximately two times higher in the cerebellum, midbrain and cortex compared to the control group. The changes of 3-HK levels were more pronounced in the striatum and medulla than in other structures. This data suggests that CRI results in deep disturbances on the kynurenine pathway in CNS, which could be responsible for neurological abnormalities seen in uremia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12183021     DOI: 10.1016/s0361-9230(02)00813-4

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  8 in total

1.  Aberrant cortical thickness in neurologically asymptomatic patients with end-stage renal disease.

Authors:  Jianwei Dong; Xiaofen Ma; Wuhong Lin; Mengchen Liu; Shishun Fu; Lihua Yang; Guihua Jiang
Journal:  Neuropsychiatr Dis Treat       Date:  2018-08-02       Impact factor: 2.570

2.  Modulation of the Paracrine Kynurenic System in Bone as a New Regulator of Osteoblastogenesis and Bone Mineral Status in an Animal Model of Chronic Kidney Disease Treated with LP533401.

Authors:  Adrian Mor; Krystyna Pawlak; Bartlomiej Kalaska; Tomasz Domaniewski; Beata Sieklucka; Marta Zieminska; Bogdan Cylwik; Dariusz Pawlak
Journal:  Int J Mol Sci       Date:  2020-08-19       Impact factor: 5.923

Review 3.  Oxidative Storm Induced by Tryptophan Metabolites: Missing Link between Atherosclerosis and Chronic Kidney Disease.

Authors:  Iwona Kwiatkowska; Justyna M Hermanowicz; Michal Mysliwiec; Dariusz Pawlak
Journal:  Oxid Med Cell Longev       Date:  2020-12-29       Impact factor: 6.543

Review 4.  The Kynurenine Pathway and Kynurenine 3-Monooxygenase Inhibitors.

Authors:  Tamera D Hughes; Osman F Güner; Emma Carine Iradukunda; Robert S Phillips; J Phillip Bowen
Journal:  Molecules       Date:  2022-01-02       Impact factor: 4.411

Review 5.  Kynurenine Pathway in Chronic Kidney Disease: What's Old, What's New, and What's Next?

Authors:  Adrian Mor; Bartlomiej Kalaska; Dariusz Pawlak
Journal:  Int J Tryptophan Res       Date:  2020-09-21

6.  A link between central kynurenine metabolism and bone strength in rats with chronic kidney disease.

Authors:  Bartlomiej Kalaska; Krystyna Pawlak; Ewa Oksztulska-Kolanek; Tomasz Domaniewski; Beata Znorko; Malgorzata Karbowska; Aleksandra Citkowska; Joanna Rogalska; Alicja Roszczenko; Malgorzata M Brzoska; Dariusz Pawlak
Journal:  PeerJ       Date:  2017-04-20       Impact factor: 2.984

Review 7.  Role of Kynurenine Pathway in Oxidative Stress during Neurodegenerative Disorders.

Authors:  Adrian Mor; Anna Tankiewicz-Kwedlo; Anna Krupa; Dariusz Pawlak
Journal:  Cells       Date:  2021-06-26       Impact factor: 6.600

Review 8.  Kynurenines as a Novel Target for the Treatment of Malignancies.

Authors:  Adrian Mor; Anna Tankiewicz-Kwedlo; Dariusz Pawlak
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.